Personalizing cancer care demands the right tools in order to get patients the right treatment at the right time. Our integrated value chain of precision oncology tools equips theranostics programs with state-of-the-art solutions at every step of the theranostics care pathway.
Theranostics for personalized
cancer care
Empowering precision oncology
cancer care
What is theranostics?
As cancer incidence rates continue to rise worldwide, there is a growing need to prioritize precision oncology.1,2 Theranostics enables precision oncology by personalizing cancer care.
Theranostics is an innovative concept of personalized therapy that focuses on both the accurate selection of patients and providing them with targeted radioligand therapy to improve their prognosis.3 It refers to structurally similar diagnostic and therapeutic agents that share a molecular-specific target that involves the use of molecular imaging techniques to identify, personalize, and monitor therapy response. It makes use of pharmaceuticals, such as radioligands, to target and treat specific areas.
By imaging with targeted radioligands (eg, 68Ga-PSMA PET), you can plan radionuclide therapies using a similar. targeted ligand labeled with a therapeutic tracer (eg, 177Lu-PSMA).4
Theranostics care pathway
Theranostics in comprehensive cancer care demands precision at every step of the patient care pathway.
There is no one-size-fits-all approach to theranostics, so no matter where your institution is on its theranostics journey, we want to empower you with the tools you need to plan, implement, and expand your program to meet the demands of tomorrow.
Our integrated theranostics value chain of precision oncology solutions
From targeted development to therapy solutions—precision oncology tools at every step of the theranostics care pathway
Molecular imaging
Our portfolio
- Biograph™ PET/CT family
with LSO and ultrafast True time of flight (TOF) - Symbia™ SPECT/CT family
with NaI crystals and absolute xSPECT™ quantification - Biograph mMR™ for hybrid PET-MR
- Automated absolute quantification solutions for PET/CT and SPECT/CT
Targeted development
PETNET Solutions, Inc.
- Clinical trial support
- Good manufacturing practice (GMP) expertise
- Established contract manufacturer of choice
- Large network of radiopharmacies
Laboratory diagnostics
Atellica® Solutions immunoassay and clinical chemistry analyzer and oncology assay portfolio
- Comprehensive therapeutic drug monitoring (TDM) menu
- Biomarker discovery, assay development, and data analysis
- Quality and regulatory expertise
Software solutions
syngo.via5 artificial intelligence
enables organ-level therapy response assessment utilizing PET/CT and SPECT/CT quantification data6
Syngo Carbon unifies all imaging data into a singular platform7
Therapy solutions
Varian
- ProBeam® 360 proton therapy system
- TrueBeam® radiotherapy system
- Halcyon™ radiotherapy system
- Ethos™ therapy
- Eclipse® treatment planning system
- Velocity™ dosimetry software
Clinical image gallery
Molecular imaging plays a role in personalizing treatment for prostate cancer, liver cancer, neuroendocrine tumors, and thyroid cancer.
The outcomes achieved by the Siemens Healthineers customers described herein were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (eg, hospital size, case mix, level of IT adoption) there can be no guarantee that others will achieve the same results.
What the experts are saying
"We're able to identify disease that we could never see before and now we know where the disease is—the entire burden of disease. Molecular imaging is an in-vivo map that allows us to tailor our detection and disease stratification as well as therapy."
Director of Molecular Imaging
Yale New Haven Health
Lawrence + Memorial and
Westerly Hospitals
New Haven, Connecticut, USA
Director of Molecular Imaging
Yale New Haven Health
Lawrence + Memorial and
Westerly Hospitals
New Haven, Connecticut, USA
The statements by Siemens Healthineers' customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.
Establishing a theranostics program
Establish an innovative theranostics program13 for tomorrow with confidence in our comprehensive value chain and trusted expertise. We are committed to personalizing theranostics solutions for you, so you can focus on personalizing care for patients.
Together, let's set the standard in precision oncology to help patients get the right treatment at the right time.
More information
Learn more about theranostics
Related Products, Services & Resources
Did this information help you?
1
World Health Organization. Worldwide cancer data. Available at https://www.wcrf.org/dietandcancer/worldwide-cancer-data/.
2
United Nations. UN projects world population to reach 8.5 billion by 2030, driven by growth in developing countries. Available at https://www.un.org/sustainabledevelopment/blog/2015/07/un-projects-world-population-to-reach-8-5-billion-by-2030-driven-by-growth-in-developing-countries/.
3
Yordanova A, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017;10:4821-4828. doi:10.2147/OTT.S140671.
4
Baum RP, et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med. 2016;57(7):1006-13. doi:10.2967/jnumed.115.168443.
5
syngo.via can be used as a standalone device or together with a variety of syngo.via-based software options which are medical devices in their own right.
syngo.via and the syngo.via-based software options are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed.
Please contact your local Siemens Healthineers organization for further details.
6
This feature is under development and is not commercially available for sale. Future availability cannot be guaranteed.
7
Syngo Carbon consists of several products which are (medical) devices in their own right. Some products are under development and not commercially available. Future availability cannot be guaranteed.
8
Lutetium oxyorthosilicate.
9
The amount of metal artifact reduction and corresponding improvement in image quality depends on a number of factors including: composition and size of the metal object, patient size, anatomical location and clinical practice. It is recommended to perform reconstruction with iMAR enabled in addition to conventional reconstruction without iMAR.
10
Compared to current state-of-the-art scanners at time of publication. Data on file.
11
Every Symbia Pro.specta configuration produces the highest image quality in its class. Based on competitive literature available at time of publication. Data on file.
12
Abdomen Dot Engine Workflow Study from Zhongshang Hospital, Fudan University, Shanghai, China.
13
Herrmann K, et al. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. Eur J Nucl Med Mol Imaging. 2022;49(7):2300-2309. doi:10.1007/s00259-022-05785-x.
The products and features (mentioned herein) are not commercially available in all countries. Future availability cannot be guaranteed.
Header image data courtesy of New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.